News Releases

Servier’s VORANIGO® (vorasidenib) and TIBSOVO® (ivosidenib) Nominated for 2026 Prix Galien International Awards

Servier completes the acquisition of Edgewise Therapeutics’ Muscular Dystrophy Business

Servier Presentations at ISPNO 2026 Highlight Neuro-Oncology Leadership and Expanding Glioma Portfolio

Servier Announces First Patient Enrolled in Phase Ib/II Study for the Treatment of a Rare Pediatric Epilepsy Syndrome in the U.S.

Promising Phase 1 Data for Servier's Emiltatug Ledadotin (Emi-Le) in Adenoid Cystic Carcinoma (ACC) Presented at ASCO 2026

Servier to Acquire Edgewise Therapeutics’ Muscular Dystrophy Business

Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026

Servier Presentations at ASCO 2026 Spotlight Expanding Rare Oncology Portfolio

Emiltatug Ledadotin (Emi-Le) Granted Breakthrough Therapy Designation by the U.S. FDA for Adenoid Cystic Carcinoma (ACC)

Day One and Servier Complete Enrollment in Pivotal Phase 3 FIREFLY-2 Trial of Tovorafenib as a Front-Line Treatment for Pediatric Low-Grade Glioma (pLGG)

Servier completes the acquisition of Day One Biopharmaceuticals

Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio

Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030

Servier's Clinical and Real-World Data at 2025 SNO Congress Showcase Leadership in IDH-Mutant Glioma

Servier's New and Updated Data at 2025 ASH Annual Meeting Highlight Commitment to Hematology Research

Servier Announces Positive Findings from Longer-Term Analysis of the Phase 3 INDIGO Trial Showing Continued Durable Treatment Effect of VORANIGO® (vorasidenib) Published in The Lancet Oncology

Servier's VORANIGO® (vorasidenib) Receives Prestigious 2025 Prix Galien USA Award

European Commission Approves Servier's VORANIGO® (vorasidenib) as the First Targeted Therapy for Grade 2 IDH-Mutant Glioma in the EU

Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder

Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide

Servier’s VORANIGO® (vorasidenib) Nominated for 2025 Prix Galien USA Award

Servier Announces Positive Data from Long-Term Follow-Up Analysis of the Phase 3 AGILE Trial of TIBSOVO® (ivosidenib) in IDH1-mutated Acute Myeloid Leukemia

Servier Receives Positive CHMP Opinion for VORANIGO® (vorasidenib) for the Treatment of Adults and Adolescents with Grade 2 IDH-mutant Diffuse Glioma

Servier Ranked Among Top Companies Across Several Categories in 2024 PatientView Corporate Reputation of Pharma Survey

Servier Presentations at ASCO 2025 Reinforce Company Leadership in IDH-Mutated Cancers